Cascadian Therapeutics (Formally known as Oncothyreon)
2601 Fourth Avenue
Suite 500
Seattle
Washington
98121
United States
Tel: 206-801-2100
Fax: 206-801-2101
Website: http://www.cascadianrx.com/
233 articles about Cascadian Therapeutics (Formally known as Oncothyreon)
-
Cascadian Therapeutics Reports Topline ONT-380 "Triplet" Data and Outlines Key Development Strategies
6/14/2016
-
Oncothyreon Announces Corporate Name Change To Cascadian Therapeutics
6/8/2016
-
ASCO2016: Oncothyreon Presents Phase Ib Results Of ONT-380 In Combination With T-DM1 In HER2+ Metastatic Breast Cancer At ASCO
6/6/2016
-
Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update
5/10/2016
-
Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors At AACR Annual Meeting 2016
4/19/2016
-
Oncothyreon Names a New CEO
3/29/2016
-
Oncothyreon Inc. Reports Full Year and Fourth Quarter 2015 Financial Results & Provides Corporate Update
3/15/2016
-
Oncothyreon Inc. Announces First Patient Dosed In Randomized Phase II ONT-380 Combination Trial In Patients With HER2-Positive Breast Cancer
2/29/2016
-
Oncothyreon Inc. Appoints Christopher Henney, Ph.D., D.Sc. As Interim CEO And Expands Board With Additions Of Mark Lampert And Gwen Fyfe, M.D.
1/11/2016
-
Oncothyreon Inc. Announces Data For ONT-380 In HER2-Positive Breast Cancer Patients With And Without Brain Metastases At The San Antonio Breast Cancer Symposium
12/9/2015
-
Oncothyreon Inc. Announces Webcast To Review Updated Clinical Data On ONT-380 In HER2-Positive Breast Cancer Patients
12/2/2015
-
Oncothyreon Inc. To Present Updated Data On ONT-380 For The Treatment Of HER2-Positive Breast Cancer At The San Antonio Breast Cancer Symposium
11/16/2015
-
Oncothyreon Inc. To Present At Rodman & Renshaw Annual Global Investment Conference
9/2/2015
-
Oncothyreon Inc. Reports Second Quarter 2015 Financial Results
8/7/2015
-
Oncothyreon Inc. Announces Second Quarter 2015 Financial Results Conference Call
7/30/2015
-
ASCO15: Oncothyreon Inc. Announces Presentation Of Positive ONT-380 Data In HER2-Positive Breast Cancer At ASCO Annual Meeting And Updates Development Plan
6/1/2015
-
Oncothyreon Inc. To Present At Jefferies and Co. 2015 Healthcare Conference
5/26/2015
-
Oncothyreon Inc. Reports First Quarter 2015 Financial Results
5/11/2015
-
Oncothyreon Inc. Announces First Quarter 2015 Financial Results Conference Call
5/4/2015
-
Oncothyreon Inc. Reports Full Year And Fourth Quarter 2014 Financial Results
3/11/2015